Your session is about to expire
← Back to Search
Other
Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders
Phase 4
Waitlist Available
Research Sponsored by Sherwood Brown, MD, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study month 30
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial
Summary
This trial tests citicoline and pregnenolone in people with alcohol use disorder and bipolar or schizoaffective disorder. These treatments aim to improve brain function, reduce alcohol cravings, and stabilize mood. Citicoline modulates phospholipids metabolism and neurotransmitter levels and appears to improve cognition in some central nervous system disorders.
Eligible Conditions
- Bipolar Disorder
- Bipolar disorder
- Alcoholism
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ study month 30
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study month 30
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Baseline-to-Exit Change in Drinks Per Drinking Day (TLFB)
Secondary study objectives
Examine the Use of an Adaptive Design in a Clinical Trial for Alcohol Use Disorder.
Side effects data
From 2016 Phase 4 trial • 62 Patients • NCT0207473517%
Drowsiness
14%
Dry mouth
14%
Nausea
10%
Diarrhea
7%
Headache
3%
Increased energy
3%
Bruising
3%
Hypertension
3%
Rash
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Citicoline
Awards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: PregnenoloneExperimental Treatment1 Intervention
Pregnenolone will be given beginning at 50 mg BID with an increase to 100 mg BID at week 1, 150 mg BID at week 2, and 250 mg BID at weeks 3-12.
Group II: CiticolineExperimental Treatment1 Intervention
Citicoline will be given beginning at 250 mg BID with an increase to 500 mg BID at week 1, 750 mg BID at week 2, and 1000 mg BID at weeks 3-12.
Group III: PlaceboPlacebo Group1 Intervention
Matching placebo given beginning at 1 capsule twice daily (BID) increasing to 2 capsules BID at week 1, 3 capsules BID at week 2, and 4 capsules BID at weeks 3-12.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pregnenolone
2011
Completed Phase 4
~770
Citicoline
2010
Completed Phase 4
~780
Find a Location
Who is running the clinical trial?
University of Texas Rio Grande ValleyOTHER
7 Previous Clinical Trials
2,579 Total Patients Enrolled
Sherwood Brown, MD, PhDLead Sponsor
University of MiamiOTHER
950 Previous Clinical Trials
428,297 Total Patients Enrolled
4 Trials studying Bipolar Disorder
280 Patients Enrolled for Bipolar Disorder